Abstract | WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: WHAT THIS STUDY ADDS: AIMS: METHODS: Data were drawn from the Norwegian Prescription Database on sales to a total of 73 964 patients in 2004 of biperiden and orphenadrine, and use in patients with Parkinson's disease or in patients who were also prescribed antipsychotic agents. Possible abuse of these drugs was assessed by the level of use, skewedness of use, indications of drug-seeking behaviour and concomitant use of benzodiazepine tranquillizers, a group of prescription drugs with a recognized potential for abuse. RESULTS: CONCLUSIONS:
|
Authors | Pål Gjerden, Jørgen G Bramness, Lars Slørdal |
Journal | British journal of clinical pharmacology
(Br J Clin Pharmacol)
Vol. 67
Issue 2
Pg. 228-33
(Feb 2009)
ISSN: 1365-2125 [Electronic] England |
PMID | 19094158
(Publication Type: Journal Article)
|
Chemical References |
- Antiparkinson Agents
- Antipsychotic Agents
- Cholinergic Antagonists
- Prescription Drugs
- Biperiden
- Orphenadrine
|
Topics |
- Adolescent
- Adult
- Aged
- Antiparkinson Agents
(therapeutic use)
- Antipsychotic Agents
(administration & dosage, adverse effects)
- Biperiden
(administration & dosage, adverse effects)
- Cholinergic Antagonists
(administration & dosage, adverse effects)
- Drug Utilization
- Female
- Humans
- Male
- Middle Aged
- Norway
(epidemiology)
- Orphenadrine
(administration & dosage, adverse effects)
- Parkinson Disease
(drug therapy, epidemiology)
- Practice Patterns, Physicians'
(standards)
- Prescription Drugs
(standards)
- Substance-Related Disorders
(diagnosis)
- Young Adult
|